NOCA Quarterly Clinical Performance Indicator Report January 2022 to December 2022 – published October 2024

The purpose of the National Ovarian Cancer Audit (NOCA) is to evaluate the patterns of care and outcomes for patients with ovarian cancer in England and Wales, and to support services to improve the quality of care for these patients.

NOCA is part of the National Cancer Audit Collaborating Centre (NATCAN), the home of the ten national cancer audits in England and Wales. This national centre of excellence was established to strengthen cancer services by evaluating the process of diagnosis and treatment, and patient outcomes in multiple cancer sites.

This is the first quarterly report published by NOCA that includes performance indicators. The quarterly report provides an overview of the performance indicators as well as quality of key data items from Rapid Cancer Registration Data (RCRD) for 4,928 women diagnosed with ovarian cancer in England between 1st January 2022 and 31st December 2022. The main cohort comprises a definition of ovarian cancer using RCRD supplied by the National Disease Registration Service (NDRS) for ICD10 codes C56 ovarian cancer, C57 fallopian tube cancer, C48 primary peritoneal cancer after excluding sarcomas, and D39.1 cancer of the ovary of uncertain or unknown behaviour.

Download your copy of the Quarterly Report below

NOCA Quarterly Report, January 2022 to December 2022

In England, NATCAN receives information from the National Cancer Registration and Analysis Service (NCRAS), part of the National Disease Registration Service (NDRS), NHS England. NDRS collects patient-level data from all NHS acute providers on patients with cancer using a range of national data-feeds. This includes the Cancer Registration datasets and the Cancer Outcomes and Services Dataset (COSD). COSD data are submitted to the NDRS monthly via Multidisciplinary Team electronic data collection systems. Clinical sign-off of data submitted to NDRS is not mandated in England. The information held in the registration dataset is compiled from a number of sources.

For this quarterly report, the NOCA utilised data from the Rapid Cancer Registration Dataset (RCRD). This dataset is compiled from a variety of sources including the Cancer Outcomes and Services Dataset (COSD), Hospital Episode Statistics admitted patient care (HES APC) records, the Systemic Anti-Cancer Therapy dataset (SACT) and data submitted by pathology laboratories and is made available more quickly than the complete cancer registration dataset. However, the speed of production means that the range of data items is limited and several standard data items in the complete registration dataset are unavailable.  It also does not have complete coverage of all women diagnosed with ovarian cancer in England during the reporting period. The data were received by the National Cancer Audit Collaborating Centre (NATCAN) between May and August 2024 and included data on women registered with ovarian cancer up to 31st May 2024.

Further information about the RCRD can be found here.

This NOCA report allocates patients to NHS organisations based on the “trust at diagnosis” recorded within the RCRD dataset.

Please note: the total number of patients from which the Cancer Alliance and NHS trust figures were derived is less than the total number of patients used for the national figures. This is because not all patients had a trust of diagnosis in the RCRD data.

Contact details

For any queries relating to the audit

Email:
[email protected]